Clinical Trials Logo
  1. Home
  2. Pelvic Organ Prolapse
  3. NCT04029168
  4. Details
NCT04029168 Clinical Trial

Pelvic Floor Muscles and Success in the Surgical Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse

Pelvic Organ Prolapse Clinical Trial

Official title:
Pelvic Floor Muscles Efficiency as an Independent Factor of Therapeutic Success in the Surgical Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04029168
Other study ID # PN/25/2019
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 1, 2019
Est. completion date July 8, 2023

Study information
Verified date July 2023
Source Zelazna Medical Centre, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of the study is evaluation of the efficiency of pelvic floor muscles in the context of surgical outcomes in the treatment of stress urinary incontinence and pelvic organ prolapse.

Recruitment information / eligibility
Status Completed
Enrollment 140
Est. completion date July 8, 2023
Est. primary completion date May 30, 2023
Accepts healthy volunteers
Gender Female
Age group 30 Years to 90 Years
Eligibility Inclusion Criteria: - premenopausal and postmenopausal women - stress urinary incontinence - pelvic organ prolapse Exclusion Criteria: - previous surgical interventions due to stress urinary incontinence or pelvic organ prolapse

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Poland Centrum Medyczne "ZELAZNA" Warsaw

Sponsors (1)
Lead Sponsor Collaborator
Zelazna Medical Centre, LLC

Country where clinical trial is conducted

Poland, 

Outcome
Type Measure Description Time frame Safety issue
Primary Pelvic Floor Distress Inventory (PFDI-20) Symptom inventory and a measure of the degree of bother and distress. The PFDI-20 includes 20 questions and 3 scales. Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 - 300. change from the baseline till 6 months post treatment
Primary Pelvic floor organ prolapse quantification (POP-Q) Quantification of pelvic organ prolapse, range 0-4, higher indicate worse outcomes change from the baseline till 6 month post treatment
Primary Marshall-Bonney test Assessment of stress urinary incontinence, test can be negative or positive, positive test indicates incontinence change from the baseline till 6 months post treatment
Secondary Pelvic Floor Distress Inventory (PFDI-20) Symptom inventory and a measure of the degree of bother and distress. The PFDI-20 includes 20 questions and 3 scales. Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 - 300. 3 months post treatment
Secondary Pelvic Floor Distress Inventory (PFDI-20) Symptom inventory and a measure of the degree of bother and distress. The PFDI-20 includes 20 questions and 3 scales. Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 - 300. 12 months post treatment
Secondary Pelvic Floor Distress Inventory (PFDI-20) Symptom inventory and a measure of the degree of bother and distress. The PFDI-20 includes 20 questions and 3 scales. Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 - 300. change from the baseline till 3 months post treatment
Secondary Pelvic Floor Distress Inventory (PFDI-20) Symptom inventory and a measure of the degree of bother and distress. The PFDI-20 includes 20 questions and 3 scales. Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 - 300. change from the baseline till 12 months post treatment
Secondary Visual Analogue Scale Distress assessment range 0-10, higher numbers represent better outcomes 3 month post treatment
Secondary Visual Analogue Scale Distress assessment range 0-10, higher numbers represent better outcomes 6 months post treatment
Secondary Visual Analogue Scale Distress assessment range 0-10, higher numbers represent better outcomes 12 months post treatment
Secondary Visual Analogue Scale Distress assessment range 0-10, higher numbers represent better outcomes change from the baseline till 3 months post treatment
Secondary Visual Analogue Scale Distress assessment range 0-10, higher numbers represent better outcomes change from the baseline till 6 months post treatment
Secondary Visual Analogue Scale Distress assessment range 0-10, higher numbers represent better outcomes change from the baseline till 12 months post treatment
Secondary PELVIC FLOOR IMPACT QUESTIONNAIRE SHORT FORM (PFIQ-7) Assessment of life impact in women with pelvic floor disorders, range 0-300, higher numbers indicate greater impact 3 month post treatment
Secondary PELVIC FLOOR IMPACT QUESTIONNAIRE SHORT FORM (PFIQ-7) Assessment of life impact in women with pelvic floor disorders, range 0-300, higher numbers indicate greater impact 6 months post treatment
Secondary PELVIC FLOOR IMPACT QUESTIONNAIRE SHORT FORM (PFIQ-7) Assessment of life impact in women with pelvic floor disorders, range 0-300, higher numbers indicate greater impact 12 months post treatment
Secondary PELVIC FLOOR IMPACT QUESTIONNAIRE SHORT FORM (PFIQ-7) Assessment of life impact in women with pelvic floor disorders, range 0-300, higher numbers indicate greater impact change from the baseline till 3 months post treatment
Secondary PELVIC FLOOR IMPACT QUESTIONNAIRE SHORT FORM (PFIQ-7) Assessment of life impact in women with pelvic floor disorders, range 0-300, higher numbers indicate greater impact change from the baseline till 6 months post treatment
Secondary PELVIC FLOOR IMPACT QUESTIONNAIRE SHORT FORM (PFIQ-7) Assessment of life impact in women with pelvic floor disorders, range 0-300, higher numbers indicate greater impact change from the baseline till 12 months post treatment
Secondary Incontinence impact Questionnaire-Short Form (IIQ-7 SF) To measure the impact of urinary incontinence on activities, roles and emotional states 3 months post treatment
Secondary Incontinence impact Questionnaire-Short Form (IIQ-7 SF) To measure the impact of urinary incontinence on activities, roles and emotional states 6 months post treatment
Secondary Incontinence impact Questionnaire-Short Form (IIQ-7 SF) To measure the impact of urinary incontinence on activities, roles and emotional states 12 months post treatment
Secondary Incontinence impact Questionnaire-Short Form (IIQ-7 SF) To measure the impact of urinary incontinence on activities, roles and emotional states change from the baseline till 3 months post treatment
Secondary Incontinence impact Questionnaire-Short Form (IIQ-7 SF) To measure the impact of urinary incontinence on activities, roles and emotional states change from the baseline till 6 months post treatment
Secondary Incontinence impact Questionnaire-Short Form (IIQ-7 SF) To measure the impact of urinary incontinence on activities, roles and emotional states change from the baseline till 12 months post treatment
Secondary Pelvic floor organ prolapse quantification (POP-Q) Quantification of pelvic organ prolapse, range 0-4, higher indicate worse outcomes at 1 month post treatment
Secondary Pelvic floor organ prolapse quantification (POP-Q) Quantification of pelvic organ prolapse, range 0-4, higher indicate worse outcomes 3 months post treatment
Secondary Pelvic floor organ prolapse quantification (POP-Q) Quantification of pelvic organ prolapse, range 0-4, higher indicate worse outcomes 12 months post treatment
Secondary Pelvic floor organ prolapse quantification (POP-Q) Quantification of pelvic organ prolapse, range 0-4, higher indicate worse outcomes change from the baseline till 3 month post treatment
Secondary Pelvic floor organ prolapse quantification (POP-Q) Quantification of pelvic organ prolapse, range 0-4, higher indicate worse outcomes change from the baseline till 12 month post treatment
Secondary Pelvic floor organ prolapse quantification (POP-Q) Quantification of pelvic organ prolapse, range 0-4, higher indicate worse outcomes change from the baseline till 1 month post treatment
Secondary Marshall-Bonney test Assessment of stress urinary incontinence, test can be negative or positive, positive test indicates incontinence at 1 month post treatment
Secondary Marshall-Bonney test Assessment of stress urinary incontinence, test can be negative or positive, positive test indicates incontinence 3 months post treatment
Secondary Marshall-Bonney test Assessment of stress urinary incontinence, test can be negative or positive, positive test indicates incontinence 12 months post treatment
Secondary Marshall-Bonney test Assessment of stress urinary incontinence, test can be negative or positive, positive test indicates incontinence change from the baseline till 3 months post treatment
Secondary Marshall-Bonney test Assessment of stress urinary incontinence, test can be negative or positive, positive test indicates incontinence change from the baseline till 1 month post treatment
Secondary Marshall-Bonney test Assessment of stress urinary incontinence, test can be negative or positive, positive test indicates incontinence change from the baseline till 12 months post treatment
Secondary Pelvic Floor Distress Inventory (PFDI-20) Symptom inventory and a measure of the degree of bother and distress. The PFDI-20 includes 20 questions and 3 scales. Each of the 3 scales is scored from 0 (least distress) to 100 (greatest distress). The sum of the scores of these 3 scales serves as the overall summary score of the PFDI-20 and ranges from 0 - 300. 6 months post treatment
Secondary Pelvic floor organ prolapse quantification (POP-Q) Quantification of pelvic organ prolapse, range 0-4, higher indicate worse outcomes 6 months post treatment
Secondary Marshall-Bonney test Assessment of stress urinary incontinence, test can be negative or positive, positive test indicates incontinence 6 months post treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05422209 - The Influence of Simultaneous Posterior Colporrhaphy and Perineoplasty on the Efficiency and Safety of Mesh-augmented Sacrospinal Fixation (Apical Sling) in Advanced POP Repair. N/A
Active, not recruiting NCT05420831 - Comparison of Vaginal and Laparoscopic Apical Fixation Techniques for Pelvic Organ Prolapse Treatment N/A
Completed NCT05493735 - Lidocaine for Pessary Check Pain Reduction Phase 3
Completed NCT06126328 - Materna Prep Study Phase II Phase 2
Recruiting NCT05542836 - EVeRLAST 2-Year Follow-Up
Recruiting NCT05918367 - Multicenter Ventral Mesh Rectopexy Registry Collaborative
Recruiting NCT04172272 - The Influence of TAP Block in the Control of Postoperative Pain After Laparotomy for Gynecological Procedures N/A
Recruiting NCT04807920 - BOTOX® at the Time of Prolapse Surgery for OAB Phase 4
Completed NCT06268782 - The Effectiveness of an Online Exercise Program on Well-being of Postpartum Women N/A
Recruiting NCT03146195 - The 3D Reconstruction Research of Pelvic Organ Prolapse Disease N/A
Recruiting NCT02919852 - Laparoscopic Retrovesical Colpopectinopexia N/A
Completed NCT02925585 - Vaginal Tactile Imaging for Pelvic Floor Prolapse
Not yet recruiting NCT02536001 - Prospective Randomized Study to Compare Results of Pelvic Organ Prolapse Repair With One Versus Two Vaginal Meshes N/A
Recruiting NCT02113969 - Conservative Management of Symptomatic Pelvic Organ Prolapse Using Vaginal Pessaries: Generation of a Standardized Management Protocol N/A
Completed NCT02383199 - Polypropylene Mesh in Prolapse Surgery N/A
Terminated NCT01673360 - Collection of Long Term Patient Outcomes Data Following Implantation of AMS Surgical Devices N/A
Completed NCT01842464 - Sacro-Spinous Ligaments Anterior Apical Anchoring N/A
Withdrawn NCT01530191 - Factors Affecting Perioperative Outcomes N/A
Completed NCT01320631 - Male Sexual Experience and Its Impact on Quality of Life Before and After Their Sexual Partners Undergo Polypropylene Mesh Augmented Pelvic Floor Reconstruction N/A
Completed NCT00581412 - Composite Graft Use in Abdominal Sacrocolpopexy Reduces Erosion Rates N/A